Authors: Derosa, G.; Gaddi, A.V.; Ciccarelli, L.; Fogari, E.; Ghelfi, M.; Cicero, A.F.G.

Source: The Journal of International Medical Research, Volume 33, Number 3, May 2005 , pp. 284-294(11)

Publisher: Field House Publishing

Abstract:

We evaluated the effect of glimepiride plus metformin and rosiglitazone plus metformin on glucose, and on cardiovascular risk parameters such as lipoprotein(a) (Lp[a]) and homocysteine (HCT) in patients with type 2 diabetes and metabolic syndrome. Ninety-nine patients in the multicentre, randomized, double-blind study took metformin (1500 mg/day) plus glimepiride (2 mg/day) or rosiglitazone (4 mg/day) for 12 months. Changes in body mass index, glycosylated haemoglobin (HbA_1c), Lp(a) and HCT were primary efficacy variables. Fasting plasma glucose (FPG), post-prandial plasma glucose (PPG) and homeostasis model assessment index were also used to assess efficacy. On average, HbA_1c decreased by 9.1% and 8.1%, FPG decreased by 7.3% and 10.9%, and PPG decreased by 7.6% and 10.5%, respectively, in the glimepiride and rosiglitazone groups after 12 months. Patients receiving rosiglitazone experienced more rapid improvement in glycaemic control than those on glimepiride, and showed a significant improvement in insulin resistance-related parameters. There was a statistically significant decrease in basal homocysteinaemia in glimepiride-treated patients (−27.3%), but not in rosiglitazone-treated patients. Rosiglitazone plus metformin significantly improved long-term control of insulin resistance-related parameters compared with glimepiride plus metformin, although glimepiride treatment was associated with a slight improvement in cholesterolaemia, not observed in the rosiglitazone-treated patients, and with significant improvements in non-traditional risk factors for cardiovascular disease, such as basal homocysteinaemia and plasma Lp(a) levels.

Articles that cite this article?

Keywords: BIGUANIDE; GLIMEPIRIDE; METFORMIN; ROSIGLITAZONE; DIABETES; LIPOPROTEIN(A); HOMOCYSTEINE; METABOLIC SYNDROME

Document Type: Research article

Publication date: 2005-05-01

More about this publication?

• The Journal of International Medical Research (JIMR) is a leading peer reviewed journal offering exceptional publication speed for medical, clinical and pre-clinical research. Reviews, case studies, preliminary communications, post-marketing surveillance, pharmacoeconomic and managed care studies are also welcome. Supplements publish symposium proceedings or collections of medical, pre-clinical or clinical data and enquiries from potential sponsors are welcome. JIMR is widely indexed and abstracted, including Medline, Current Contents and Excerpta Medica (EMBASE).
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Internal Medicine ,  Pharmacology ,  Public Health
• By this author: Derosa, G. ;  Gaddi, A.V. ;  Ciccarelli, L. ;  Fogari, E. ;  Ghelfi, M. ;  Cicero, A.F.G.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers